Deals this week: Sitryx, Keen Eye, Accera

12th October 2018 (Last Updated August 12th, 2019 10:38)

Sitryx has raised $30m in a Series A financing round led by SV Health Investors and Sofinnova Partners.

Sitryx has raised $30m in a Series A financing round led by SV Health Investors and Sofinnova Partners.

The funds will be utilised for the development of disease-modifying treatments for cancer and auto-immune diseases, and other conditions.

Based in the UK, Sitryx is a biopharmaceutical company engaged in the development of therapies in the areas of immuno-oncology and immuno-inflammation.

Keen Eye has partnered with Iris Pharma to provide artificial intelligence (AI) applications to the latter to deliver efficient ophthalmology assays.

Based in France, Keen Eye is a bio-imaging company focused on the use of innovative technologies for the development of therapies, while Iris Pharma, also based in France, is an ophthalmology-based contract research organisation (CRO).

The partnership will enable Iris to improve image-based assays for combating eye diseases.

Accera has raised $50m in a new investment round led by Wilmar Ventures, under a new company named Cerecin.

Inventages and a Nestle Group-backed healthcare-focused private equity fund were the other investors.

The fund will be utilised in Ceracin’s drug development activities globally and in the launch of Axona®, a medical food to manage the diet of Alzheimer’s disease patients.

"Keen Eye has partnered with Iris Pharma to provide artificial intelligence (AI) applications to the latter to deliver efficient ophthalmology assays."

Based in the US, Accera is a biotechnology company focused on the development of central nervous system disorder therapies, while Wilmar Ventures is a Singapore-based investment arm of agribusiness group Wilmar International.

Rgenix has secured $40m in a Series C financing round led by Lepu Medical.

Oceanpine Capital, WuXi AppTec’s Corporate Venture Fund, Novo Holdings, Sofinnova Partners, Alexandria Venture Investments, and the Partnership Fund for New York City’s Innovate NY Fund and associated entities also participated in the round.

Based in the US, Rgenix is a biopharmaceutical company focused on the development of oncology therapeutics.

The fund will be utilised for the further development of candidates in the company’s pre-clinical and clinical stages of development.

Gotham Therapeutics has raised $54m in a Series A funding round led by Versant Ventures, Forbion, and S.R. One.

Celgene Corporation and Alexandria Venture Investments also participated in the round.

The funding will be used towards the development of a platform to analyse the effect of RNA-modifying proteins on disease mechanism for the development of therapeutics.

Based in the US, Gotham Therapeutics is a biotechnology company focused on the development of therapeutics targeting epitranscriptomics machinery.